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Little is known about the maintenance of intestinal
stem cells (ISCs) and progenitors during immune-
mediated tissue damage or about the susceptibility
of transplant recipients to tissue damage mediated
by the donor immune system during graft versus
host disease (GVHD). We demonstrate here that defi-
ciency of recipient-derived IL-22 increased acute
GVHD tissue damage and mortality, that ISCs were
eliminated during GVHD, and that ISCs as well as
their downstream progenitors expressed the IL-22
receptor. Intestinal IL-22 was produced after bone
marrow transplant by IL-23-responsive innate
lymphoid cells (ILCs) from the transplant recipients,
and intestinal IL-22 increased in response to pre-
transplant conditioning. However, ILC frequency
and IL-22 amounts were decreased by GVHD. Recip-
ient IL-22deficiency led to increasedcrypt apoptosis,
depletion of ISCs, and loss of epithelial integrity. Our
findings reveal IL-22 as a critical regulator of tissue
sensitivity to GVHD and a protective factor for ISCs
during inflammatory intestinal damage.
INTRODUCTION
Although potentially curative for benign and malignant hemato-
poietic diseases, allogeneic hematopoietic transplantation
continues to be limited by severe morbidity andmortality caused
by graft versus host disease (GVHD) (Wingard et al., 2011). Acute
GVHD occurs when alloreactive donor T cells activated against
recipient antigens attack vital recipient organs, classically theskin, liver, and gastrointestinal (GI) tract (Shlomchik, 2007). GI
GVHD in particular is a major contributor to transplant morbidity
and mortality because skin GVHD can often be controlled
without systemic immunosuppression and liver GVHD is much
less frequent (Hill and Ferrara, 2000).
Although substantial progress has been made toward under-
standing the donor immune response directed against recipient
tissues, there is little insight into the factors regulating sensitivity
of recipient tissues to GVHD. Additionally, although the GVH
immune response has long been felt to involve an attack against
the intestinal stem and progenitor cell niche, there has been
little direct evidence demonstrating the loss of intestinal stem
cells (ISCs) during GVHD. Furthermore, there is little under-
standing of the role that tissue stem cell damage plays in other
models of inflammatory epithelial injury. Given the limitations
of existing immunosuppression-based therapies for GVHD, our
currently poor understanding of the recipient response to
GVHD, and our poor understanding of how recipient tissues
recover from GVHD-induced damage, we sought to identify
novel factors that could selectively regulate GI injury resulting
from GVHD. Furthermore, we sought to do so by focusing on
protection of recipients at the tissue level and at the level of
ISCs. This rationale is supported by the recent demonstration
that treatment with Wnt signaling agonists can provide a
trophic signal for intestinal epithelium during GVHD (Takashima
et al., 2011). Moreover, although steady state regulation of
the intestinal stem and progenitor cell niche is thought to be
a complex orchestration of Wnt, bone morphogenetic protein,
Notch, and Hedgehog signaling (Medema and Vermeulen,
2011), there is little knowledge of ISC niche regulation during
intestinal damage.
IL-22 is a recently characterized cytokine produced by several
hematopoietic populations, including helper T (Th) cells and
innate lymphoid cells (ILCs) (Liang et al., 2006; Spits and Di
Santo, 2011), and expression of the IL-22 receptor (IL-22R) isImmunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc. 339
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IL-22 Protects ISCs and Regulates GVHDrestricted to nonhematopoietic stromal cells (Pickert et al.,
2009; Tachiiri et al., 2003; Witte et al., 2010; Wolk et al., 2004;
Zenewicz et al., 2007). IL-22 has contrasting inflammatory and
cytoprotective effects, leading to pathologic inflammation
and excessive stimulation of keratinocytes in psoriasis while
limiting toxicity in models of acute hepatitis and DSS-induced
colitis (Pickert et al., 2009; Sonnenberg et al., 2011a;
Wolk et al., 2006). IL-22 protects intestinal epithelium during
inflammatory bowel disease (IBD) and experimental colitis by
providing a signal for epithelial cell survival, proliferation, and
wound healing (Pickert et al., 2009), but impacts of IL-22
on the stem and progenitor cell compartment are unknown.
Given the parallels between IBD and GI GVHD (Asplund
and Gramlich, 1998), we reasoned that IL-22 signaling could
function to protect recipient intestinal tissue after bone marrow
transplant (BMT) without limiting donor immunity and utilized
clinically relevant mouse models of GVHD to evaluate the rela-
tionship between inflammatory tissue damage and epithelial
regeneration.
RESULTS
Deficiency of Recipient-Derived IL-22 Increases
GI GVHD
In order to test the hypothesis that IL-22 signaling protects
recipients from GVHD, we first tested an aggressively lethal
MHC-mismatched murine BMT model of C57BL/6 (B6, H-2b)
donor marrow and T cells transplanted into lethally irradiated
BALB/c (H-2d) recipients. Although transplantation of T cell-
depleted allogeneic bone marrow (BM) rescues recipient mice
from lethal total body irradiation (TBI), transplantation of
allogeneic marrow and T cells leads to GVHD. Elimination of
IL-22 with an IL-22-neutralizing antibody led to a significant
increase in GVHDmortality (Figure 1A). However, transplantation
with IL-22-deficient (Il22/) donor marrow or T cells had no
impact on GVHD survival (Figures 1B and 1C). In contrast,
Il22/ BMT recipients demonstrated significantly increased
GVHD mortality (Figure 1D), suggesting a critical role for host
cells in the production of protective IL-22 post-BMT. The impor-
tance of recipient-derived IL-22 was confirmed in a MHC-
matched (H-2b) BMT model with minor histocompatibility
antigen (MiHA) disparity (LP/B6), which is similar to clinical
matched unrelated donor transplantation. Il22/ recipients
again had significantly increased GVHD mortality and GVHD-
associated organ pathology in the small and large intestine
and liver (Figures 1E and 1F). The increased histopathologic
scoring identified in the intestines of Il22/ recipients was due
to increased epithelial damage despite similar inflammatory
activity during GVHD (Figure S1A available online). No differ-
ences in skin GVHD pathology were observed in Il22/ recipi-
ents (Figure S1B).
Because certain host-derived hematopoietic cells can persist
in recipient tissues post-BMT (Merad et al., 2004), we hypothe-
sized that IL-22 could be produced by a subset of radio-resistant
hematopoietic cells within recipient target organs. We thus
generated hematopoietic chimeras for use as secondary trans-
plant recipients by reconstituting CD45.1 B6 congenic mice
with Il22/ or wild-type (WT) CD45.2 B6 marrow (Figure 1G).
Hematopoietic reconstitution was confirmed 3 months later by340 Immunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc.sampling peripheral blood (>90% in all cases). Chimeric recipi-
ents were then transplanted with allogeneic LP marrow and
T cells in a reduced-intensity transplant model designed for
mice undergoing secondary transplantation. IL-22 deficiency
restricted to the recipient hematopoietic compartment resulted
in increased GVHD morbidity and mortality (Figures 1G and
1H), indicating that the source of protective IL-22 was residual
host-derived hematopoietic cells. In contrast, depletion of all
donor-derived IL-22 by transplantation with both Il22/marrow
and Il22/ T cells did not increase GVHD mortality, further
demonstrating that protective IL-22 was produced by a recip-
ient-derived source (Figure 1I). This combined donor marrow
and T cell IL-22 deficiency led to a statistically significant delay
in GVHD mortality, suggesting a potentially additive proinflam-
matory effect of IL-22 produced by donor-derived cells.
Intestinal IL-22 Expression Is Increased after
Pretransplant Conditioning but Reduced by GVHD
Given that recipient-derived IL-22 appeared to play a critical
protective role in the development of GVHD, we next sought to
determine the normal pattern of IL-22 expression post-BMT.
Serum IL-22 concentrations were measured by ELISA in
transplanted mice and untransplanted controls. Serum IL-22
concentrations were increased after both B6/BALB/c (MHC-
mismatched) and LP/B6 (MiHA-mismatched) BMT. However,
this increase in serum IL-22 concentrations post-BMT was not
observed in transplanted mice with GVHD (Figure 2A). IL-22
ELISA on small and large intestine homogenates after LP/B6
BMT indicated that IL-22 protein was increased from baseline
3 weeks post-BMT in recipients without GVHD. However, similar
to the serum expression pattern, intestinal IL-22 concentrations
were lower in BMT recipients with GVHD than in recipients
without GVHD (Figure 2B). Although reduced IL-22 protein in
GVHD intestines could have been due to increased cytokine
turnover in damaged tissues, this interpretation was refuted
by the dual observations that IL-22 protein production was
decreased during overnight culture of GVHD intestines and
IL-22 mRNA was decreased in the lamina propria of GVHD
mice (Figure S2). Consistent with increased host-derived IL-22
production post-BMT, sublethal TBI without transplantation
also led to significantly elevated IL-22 protein in homogenized
intestines (Figure 2C).
IL-23, which is produced by antigen presenting cells post-
BMT (Das et al., 2009), has been reported as a major regulator
of IL-22 production (Cella et al., 2009; Kreymborg et al., 2007;
Sonnenberg et al., 2011b; Zheng et al., 2007). Consistent with
this, we found that IL-22 protein was not elevated in homoge-
nized intestines of p40-deficient mice (Il12b/, lacking IL-23
and IL-12) 3 weeks after sublethal TBI (Figure 2D). Similarly to
observations following MHC-mismatched transplantation (Das
et al., 2009), IL-23 concentrations were elevated in tissue
homogenates from lethally irradiated WT mice 2 weeks after
MiHA-mismatched BMT (Figure 2E). Intestinal IL-23 was also
elevated 1 week after lethal radiation without transplantation
(Figure 2F), although IL-22 concentrations were not yet
elevated at that time (data not shown). Kinetics of IL-23 expres-
sion thus preceded those of IL-22, suggesting that initial produc-
tion of IL-23 post-BMT may have induced subsequent IL-22
expression.
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Figure 1. Host IL-22 Deficiency Increases GVHD
(A–D) BALB/c recipient mice were transplanted with B6 T cell-depleted marrow alone or with marrow and T cells (MHC mismatch). As shown in (A), IL-22
neutralizing antibody or isotype control was given to mice by intraperitoneal administration three times per week until day 30 post-BMT. The graph shows
shortenedmedian survival time in GVHDmice treatedwith neutralizing antibody. As shown in (B), micewere transplantedwith Il22/ orWT donormarrowwith no
change in median survival. As shown in (C), mice were transplanted with Il22/ or WT donor T cells with no change in median survival. As shown in (D), BMT was
performed into BALB/c Il22/ or WT BMT recipients. The graph shows shortened median survival time in Il22/ recipients with GVHD.
(E–H) B6 recipient mice transplantedwith LP T cell-depletedmarrow ormarrow and T cells (minor antigenmismatch). As shown in (E), BMTwas performed into B6
Il22/ or WT BMT recipients. The graph shows shortened median survival time in Il22/ recipients with GVHD. As shown in (F), the graph shows GVHD
histopathology 3 weeks after BMT into Il22/ or WT recipients. As shown in (G), BMT was performed with B6 WT chimeras (WT/WT) or hematopoietic Il22/
chimeras (Il22//WT) as recipients of LP WT donor cells. The graph shows survival time. In (H), the graph shows clinical GVHD scoring for chimeric BMT
recipients shown in (G).
(I) BALB/c recipient mice were transplanted with either B6 WT marrow, Il22/ marrow, WT marrow, and WT T cells or Il22/ marrow and Il22/ T cells. The
graph shows survival time. Data are combined (A–G, I) or representative (H) of at least two independent experiments and at least nine mice per group; bar graphs
show the mean and SE. *p < .05, **p < .01, ***p < .001.
Immunity
IL-22 Protects ISCs and Regulates GVHDIL-22 Is Produced Post-BMT by Radio-Resistant Host
ILCs that Are Eliminated during GVHD
Because IL-22 was expressed post-BMT and was derived from
recipient hematopoietic cells, we next sought to identify the
cellular source of intestinal IL-22 after BMT. ILCs contribute to
lymphoid ontogeny and intestinal immunity and are potent
sources of IL-22 (Sonnenberg et al., 2011a; Spits and Di Santo,
2011). Lamina propria ILCs were identified post-BMT by flow
cytometry on the basis of their expression of RORgt in the
absence of CD3 (Figure S3). We observed that CD45+CD3
RORgt+ ILCs could persist post-BMT in the lamina propria of
transplantedmice without GVHD, but were reduced in frequency
and total numbers in BMT recipients with GVHD (Figure 3A). ILCsproduced IL-22 in response to IL-23 stimulation in vitro (Fig-
ure 3B) and were of host origin (Figure 3C). However, host
IL-22-producing ILCs were eliminated during GVHD (Figure 3D).
This was confirmed in MiHA-disparate recipients with GVHD
(Figure 3E), and similar results were observed in large intestine
as well (data not shown). Although IL-22 can be produced by
other lymphoid populations such as Th17 cells and natural killer
cells (Witte et al., 2010), no significant IL-22 production was iden-
tified in lamina propria subsets expressing the T cell marker CD3
or lacking RORgt (Figure S3). Phenotypic assessment of IL-22+
ILCs post-BMT indicated NKp46 cells with expression of
IL-7Ra and CCR6 (Figure 3F), consistent with the phenotype of
a lymphoid tissue inducer-like cell (Sawa et al., 2010). Thus,Immunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc. 341
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Figure 2. IL-22 and IL-23 Are Produced after Pretransplant Conditioning
(A) IL-22 ELISA was performed on serum from BALB/c and B6 mice 2 weeks after B6/BALB/c BMT or 3 weeks after LP/B6 BMT. Graphs show serum IL-22
concentrations. Data are representative of two independent experiments with at least four mice per group in each experiment.
(B–F) Cytokine ELISA was performed on homogenized intestinal tissue from B6 mice. In (B), the graph shows intestinal IL-22 concentrations after LP/B6 BMT.
In (C), the graph shows intestinal IL-22 concentrations after sublethal 550 cGy TBI of WT B6 mice. In (D), the graph shows fold increase in intestinal
IL-22 concentrations after sublethal 550 cGy TBI of WT versus p40-deficient (Il12b/) B6 mice lacking IL-23 and IL-12. In (E), the graph shows intestinal
IL-23 concentrations after LP/B6 BMT without T cells. In (F), the graph shows intestinal IL-23 concentrations after lethal 1100 cGy TBI, split dose. In all
panels, data are combined from at least two independent experiments and at least seven mice per group; bar graphs show mean and SE. *p < .05, **p < .01,
***p < .001.
Immunity
IL-22 Protects ISCs and Regulates GVHDILCs are the recipient-derived source of IL-22 post-BMT, and
they are reduced during aggressive experimental (MHC-mis-
matched) and clinically modeled (MHC-matched) GVHD.
In order to determine how recipient-derived ILCs could persist
post-BMT despite lethal pretransplant conditioning, we evalu-
ated the sensitivity of lamina propria ILCs to radiation treatment.
Assessment of ILCs in B6 lamina propria 24–72 hr after lethal
(1100 cGy) TBI indicated no significant change in the absolute
numbers of ILCs postradiation (Figure 4A). ILC frequency in
lamina propria increased 24 hr after radiation treatment (Fig-
ure 4B), further indicating a relative resistance of ILCs to radia-
tion as compared to other CD45+ lamina propria cells. We also
assessed the sensitivity of intestinal T cells to radiation treat-
ment. In contrast to the ILCs, lamina propria CD4+ T cells
decreased in frequency 72 hr after TBI (Figure 4C). This led to
an increase in the ILC-to-CD4 ratio after TBI, providing further
evidence of the radio resistance of ILCs (Figure 4D).
Given the short-term radio resistance of ILCs and the persis-
tence of recipient-derived ILCs early after T cell-depleted BMT,
we performed a long-term assessment of the ILC chimerism
up to 3 months post-BMT. In the periphery, the CD11b+ myeloid
cells were fully of donor origin by 2 months post-BMT, indicating
donor hematopoietic stem and progenitor cell engraftment (Fig-
ure 4E). Consistent with this donor hematopoietic engraftment,
lamina propria T cells were primarily donor derived and new
donor-derived ILCs were also identified in recipient lamina
propria 2 months post-BMT (Figure 4E). Interestingly, despite342 Immunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc.the donor hematopoietic engraftment in both myeloid cells and
in T cells in the periphery and in T cells within the GI lamina prop-
ria, the ILCs in recipient lamina propria remained primarily recip-
ient-derived even 3 months post-BMT (Figures 4F and 4G).
Host IL-22 Deficiency Does Not Significantly Alter
the Donor Immune Response
Because recipient-derived IL-22+ ILCs could persist post-BMT
and IL-22 expression increased post-BMT in mice without
GVHD, we sought to determine how deficiency of recipient-
derived IL-22 could lead to increased GVHD. Given that GVHD
is mediated by donor T cells, we assessed for differences in
the donor T cell compartment after transplant into WT or Il22/
recipients (Figure 5). Although host IL-22 deficiency led to
increased GVHD mortality and intestinal pathology, no differ-
ences were observed in lymphocyte infiltration of recipient
intestines (Figure 5A). Furthermore, no major differences were
observed in frequencies of donor lymphoid subsets within
recipient spleen or mesenteric lymph nodes (Figure 5B), and no
differences were observed in donor T cell production of IFN-g or
TNF-a (Figure 5C). Therefore, although increased GVHD was
observed in Il22/ recipients, this did not appear to be due to
increased donor alloreactivity.
Intestinal Stem Cells Are Targets of GVHD
Consistent with direct protection of recipient epithelium by IL-22
after transplant, IL-22R expression was significantly increased
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Figure 3. IL-22 Is Produced Post-BMT by IL-23-Responsive Host ILCs that Are Eliminated during GVHD
Detection of CD45+CD3RORgt+ ILCs 2 weeks after BMT by flow cytometry of small intestine lamina propria cells after 5 hr of IL-23 stimulation in vitro.
(A–D) B6/BALB/c BMT was performed with T cell-depleted marrow alone or with marrow and T cells. In (A), the graph shows frequency of CD3RORgt+ ILCs
among CD45+ lamina propria cells and total numbers of CD45+CD3RORgt+ lamina propria ILCs from recipients with (BM + T cells) or without (BM only)
GVHD. In (B), plots show concatenated frequencies of IL-22-producing RORgt+ ILCs. The bar graph shows frequencies of IL-22+RORgt+ ILCs among all RORgt+
ILCs. In (C), the plot shows detection of H-2d+ host-derived cells among IL-22-producing ILCs identified after BM-only BMT shown in (B). In (D), the graph shows
total host IL-22-producing ILCs after B6/BALB/c BMT. Data are representative of three independent experiments and at least 13 mice per group.
(E and F) LP/B6 BMTwas performed with T cell-depletedmarrow alone or with marrow and T cells. In (E), the graph shows total host IL-22-producing ILCs after
LP/B6BMT. In (F), plots show NKp46IL-7Ra+CCR6+ phenotype of IL-22-producing CD45+CD3RORgt+ ILCs after BM-only BMT. In all panels, data are
representative of two independent experiments and at least six mice per group; bar graphs show mean and SE. *p < .05, **p < .01.
Immunity
IL-22 Protects ISCs and Regulates GVHDpost-BMT in small and large intestines of WT recipients regard-
less of GVHD (Figures 6A and 6B). In addition to mature villus
epithelium, immunohistochemistry identified IL-22R expression
within intestinal crypts where the epithelial stem and progenitor
cell niche is located (Figure 6C) (Medema and Vermeulen,
2011; Simons and Clevers, 2011). Lgr5+ ISCs, termed crypt
base columnar (CBC) cells for their histologic location and
morphology, are capable of generating entire crypt-villus struc-
tures in vitro and in vivo (Barker et al., 2007; Sato et al., 2009).
Paneth cells provide a supportive microenvironment for ISCs
in vivo at least in part by activating Wnt signaling within ISCs
(Sato et al., 2011). Immunohistochemistry thus appeared to
identify IL-22R expression on both epithelial progenitors at theapex and ISCs at the crypt base between Paneth cells (Fig-
ure 6C). Immunofluorescence further demonstrated IL-22R
expression on ISCs located between lysozyme-expressing
Paneth cells, in addition to IL-22R expression on ISC progeny
higher in the crypt (Figure 6D). This was confirmed by flow
cytometry for IL-22R on Lgr5-GFP reporter crypt epithelial cells
(Barker et al., 2007), in which GFP+ cells were also found to
express IL-22R (Figure S4). IL-22R expression is thus increased
post-BMT, and IL-22R is expressed within the intestinal stem
and progenitor cell compartment.
GVHD attacks recipient intestinal epithelium, and it is thought
to include an attack against epithelial precursors. However,
definitive data demonstrating the elimination of ISCs duringImmunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc. 343
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Figure 4. ILCs Are Radio Resistant and Persist Long-Term Post-BMT
(A–D) Flow cytometrywas performed on lamina propria cells fromB6 small intestine 24–72 hr after lethal TBI (550cGy3 2). In (A), the graph shows total numbers of
intestinal CD45+CD3RORgt+ ILCs after TBI. In (B), the graph shows frequency of CD3RORgt+ ILCs among lamina propria CD45+ cells after TBI. In (C), the graph
shows frequency of CD4+ T cells among lamina propria CD45+ cells after TBI. In (D), the graph shows ratio of ILCs to CD4+ T cells after TBI.
(E–G) Donor and host chimerism of peripheral myeloid cells, peripheral T cells, small intestine lamina propria T cells, and small intestine lamina propria ILCs was
measured by flow cytometry after T cell-depleted B6/BALB/c allogeneic BMT. In (E), the graph shows chimerism 2 months post-BMT. In (F), the graph shows
chimerism 3 months post-BMT. Data are combined (A–F) or representative (G) of at least two independent experiments with at least five mice per group; bar
graphs show mean and SE. *p < .05, ***p < .001.
Immunity
IL-22 Protects ISCs and Regulates GVHDGVHD have been limited prior to the identification of ISC-specific
markers. Takashima et al. (2011) reported that GVHD impaired
the recovery of ISCs from radiation injury and that treatment
with the ISC growth factor R-spondin1 could promote epithelial
recovery and reduce systemic GVHD. In order to examine ISC
damage during GVHD, we utilized B6 Lgr5-LacZ reporter mice
as recipients during MiHA-mismatched transplantation. Lgr5-
expressing cells were identified by LacZ staining, and transplan-
tation demonstrated a significant reduction of LacZ-expressing
CBC cells in BMT recipients with GVHD (Figure 6E). This indi-
cates that ISCs are eliminated duringGVHDdespite their expres-
sion of IL-22R, which is consistent with our findings that IL-22
and IL-22-producing ILCs were reduced during GVHD.
IL-22 Deficiency Leads to Increased Epithelial Damage
during GVHD and Loss of ISCs
Given the lack of a major discernible impact on alloreactive
donor immunity during IL-22 deficiency, the expression of IL-
22R on intestinal stem and progenitor cells, and the loss of
ISCs during GVHD, we sought to determine how IL-22 could
act upon recipient epithelium to protect against GVHD. In addi-
tion to having a greater overall GVHD score post-BMT, blinded
histopathologic assessment indicated an increase in epithelial
apoptosis within intestinal crypts of Il22/ recipient mice during
GVHD (Figure 7A). Given that the intestinal stem and progenitor
niche is located within epithelial crypts, and that these cells344 Immunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc.express IL-22R, we next compared the stem cell compartment
in WT and Il22/ recipient mice during GVHD (Figure 7B).
Similar to what was observed with Lgr5-LacZ reporter mice,
blinded histologic assessment of the ISC niche indicated that
WT recipients without the b-galactosidase reporter also demon-
strated a loss of CBC cells during GVHD (Figure 7B, WT recipi-
ents transplanted +/ donor T cells), confirming that ISCs were
GVHD targets. Moreover, loss of ISCs in Il22/ recipients with
GVHD was significantly worse than the loss of ISCs in WT mice
(Figure 7B). These findings indicate that IL-22 is not only capable
of protecting mature intestinal epithelium, but that IL-22 can also
protect ISCs.
Given the regulation of epithelial cell production of Reg family
molecules by IL-22 (Sanos et al., 2011), we examined the expres-
sion of Reg3g and Reg3bmRNA during GVHD in WT and Il22/
recipients. Both molecules are known to be produced by intes-
tinal epithelium in response to IL-22, and, in addition to their
direct antimicrobial properties, Reg3b has also been reported
to promote epithelial cell proliferation and protection from
apoptosis in response to tissue injury (Kinnebrew et al., 2012;
Okamoto, 1999; Pickert et al., 2009; van Ampting et al., 2012).
Consistent with the overall increased mortality and epithelial
damage of Il22/ mice during GVHD, expression of Reg3g
and Reg3b mRNA were both reduced during GVHD in Il22/
mice as compared to WT GVHD mice (Figures 7C and 7D).
Finally, in order to test the epithelial consequences of increased
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Figure 5. Donor Immunity Is Not Significantly Altered by Host IL-22 Deficiency
(A) Histopathologic assessment of lymphocyte infiltration was performed on intestinal tissues from WT or Il22/ recipients 3 weeks after LP/B6 BMT. Graphs
show histopathologic scoring of lymphocytic infiltrates.
(B and C) Splenocytes andmesenteric lymph node (MLN) cells fromWT or Il22/ recipients were analyzed with flow cytometry 2 weeks after B6/BALB/c BMT.
In (B), graphs show frequencies and total numbers of donor lymphoid subsets among all splenocytes or among all MLN cells. In (C), graphs show frequencies
among donor CD4+ T cells and total numbers of all donor CD4+ T cells expressing IFN-g or TNF-a after stimulation in vitro with PMA and ionomycin. In all panels,
data are combined from two independent experiments with at least nine mice per group; bar graphs show mean and SE. *p < .05, ***p < .001.
Immunity
IL-22 Protects ISCs and Regulates GVHDapoptosis, loss of CBC cells, and reduced Reg3g and Reg3b in
Il22/ recipient mice, we tested epithelial barrier function in
BMT recipients by performing oral administration of FITC-
dextran, a nonabsorbed carbohydrate that enters the blood-
stream if the epithelial barrier has been compromised (Brandl
et al., 2009; Kabashima et al., 2002; Yan et al., 2009). Challenge
with oral FITC-dextran indicated increased GVHD-related
epithelial damage and loss of epithelial integrity in Il22/ BMT
recipients (Figure 7E). Thus, with an equivalent donor immune
response, Il22/ recipient mice suffered increased mortality,
intestinal pathology, damage to the ISC compartment, and
compromised epithelial barrier function.
DISCUSSION
Little is known about the susceptibility of transplant recipients to
tissue damage mediated by the donor immune system and the
regenerative mechanisms employed by recipient tissues to
recover from this immune-mediated damage. Although alter-
ation of GVHD by recipient-derived factors has previously been
described, the primary effect of these molecules has been on
the activation of the donor immune system (Lin et al., 2003;
Penack et al., 2010). A clinical parameter of transplant patients
that has been linked to their risk for developing GVHD is
increased recipient age (Flowers et al., 2011; Nash et al.,
1992). However, specific mechanistic etiologies for the suscep-
tibility of older adults to GVHD are unclear, and acute GVHD
susceptibility can be difficult to separate from toxicity becauseof pretransplant conditioning (Jagasia et al., 2012). Factors
such as DNA repair mechanisms may regulate damage from
conditioning (Dalle, 2008), and indoleamine 2,3-dioxygenase
may regulate repair mechanisms as well as immune effects
(Jasperson et al., 2008), but specific regulation of GVHD suscep-
tibility remains poorly understood. In our study, host IL-22
deficiency led to increased GVHD morbidity and mortality.
With the lethal pretransplant conditioning doses used here,
IL-22-deficient recipients demonstrated increased intestinal
pathology specifically in the inflammatory setting of GVHD, but
not after conditioning and transplantation in the absence of
donor T cells. Host IL-22 deficiency did not significantly alter
the alloreactive donor immune response; however, it did
increase GVHD in two distinct model systems, worsen epithelial
apoptosis, and compromise the integrity of the intestinal barrier
function. These findings indicate that IL-22 is an important recip-
ient-derived factor with a primary role in regulating recipient
sensitivity to GVHD.
In our study, deficiency of recipient-derived IL-22 led to
increased GVHD pathology in the intestines and liver, although
no differences were observed in GVHD of the skin. The impor-
tance of IL-22 in protecting recipients from GVHD was clearly
demonstrated by the use of an IL-22 neutralizing antibody after
allogeneic BMT. Although deficiency of IL-22 derived from either
donor marrow or from donor T cells was not found to impact
mortality after transplantation with Il22/ donor cells, we identi-
fied that combined transplantation with marrow and T cells that
were both deficient in IL-22 led to a modest but statisticallyImmunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc. 345
Figure 6. IL-22R Is Expressed in Intestinal Crypts, and Intestinal Stem Cells Are Targets of GVHD
(A and B) LP/B6 BMT was performed with T cell-depleted marrow alone or with marrow and T cells. IL-22R expression was measured by flow cytometry
performed on epithelial cells from normal or transplanted WTmice 3 weeks post-BMT. In (A), the graph shows small intestine (SI) epithelial cell IL-22RMFI. In (B),
the graph shows large intestine (LI) epithelial cell IL-22R MFI.
(C) Immunohistochemistry was performed on tissue sections from untransplanted B6 small intestine. A schematic is shown depicting intestinal stem cells (ISCs),
progenitor cells, and Paneth cells within a small intestine crypt. ISCs expressing Lgr5 are histologically referred to as crypt base columnar (CBC) cells on the basis
of their location and morphology. Immunohistochemistry images show serial sections stained with either an IL-22R antibody or isotype control. Brown staining
indicates IL-22R expression in progenitor layer (brackets) and on CBC cells (green arrows) between Paneth cells (red arrows) at crypt base.
(D) Immunofluorescence was performed on serial sections from untransplanted B6 small intestine stained with either an IL-22R antibody or isotype control.
Images demonstrate IL-22R (green), lysozyme (red), and nuclear (blue) staining, indicating IL-22R expression by progenitors (brackets) above and CBC cells
(green arrows) between lysozyme-expressing Paneth cells (red granules).
(E) LP/B6 allogeneic BMT was performed with Lgr5-LacZ reporter mice used as recipients. Images show a close-up of Lgr5-expressing small intestine CBC
cells from untransplanted B6 Lgr5-LacZ reporter mice and circumference views of small intestines from B6 Lgr5-LacZ reporter mice without transplantation,
post-BMT without GVHD, and post-BMT with GVHD. The graph shows small intestine Lgr5+ CBC frequencies for B6 reporter mice without transplantation and
post-BMT. In all panels, data are representative of at least two independent experiments and at least seven mice per group; bar graphs show mean and SE.
*p < .05, **p < .01, ***p < .001.
Immunity
IL-22 Protects ISCs and Regulates GVHDsignificant increase in median survival. Although the dominant
effect appears to be epithelial protection by IL-22 given the
results of IL-22 neutralizing antibody treatment, these findings
suggest that the same cytokine produced by donor versus recip-
ient-derived sources may have opposing effects on GVHD-
related tissue damage. Further investigation will be required to346 Immunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc.determine which effect is dominant in clinical transplantation
and whether exogenous IL-22 administration will yield a protec-
tive or proinflammatory outcome.
Significant progress has recently been made in the under-
standing of IL-22 and immune-mediated regulation of epithelial
maintenance and regeneration (Sonnenberg et al., 2011a). An
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Figure 7. IL-22 Deficiency Leads to Increased Epithelial Damage and Loss of Intestinal Stem Cells
LP/B6 BMT was performed with WT or Il22/ recipients and analyzed 3 weeks post-BMT.
(A) Histopathologic assessment of apoptosis in crypt epithelium was performed on tissue sections from transplanted mice. The graph shows histopathologic
apoptosis score for intestinal tissues from BMT recipients transplanted with or without T cells. The image shows representative TUNEL staining on serial sections
from small intestine post-BMT, confirming apoptosis (black arrows) in crypt epithelium of Il22/ recipients during GVHD.
(B) Histologic assessment of small intestine CBC cells was performed on tissue sections fromWT and Il22/ recipients with (BM + T) or without (BM only) GVHD.
The graph shows small intestine CBC frequencies in nonreporter mice post-BMT.
(C andD) Quantitative PCR for Reg3g and Reg3bmRNAexpressionwas performed on colon samples fromWT versus Il22/ recipients withGVHD.Graphs show
Reg3g and Reg3b relative expression in colons after BMT with marrow and T cells.
(E) BMT recipients of marrow and T cells were challenged with oral gavage of FITC-dextran 3 weeks post-BMT. The graph shows plasma FITC-dextran
concentrations in WT versus Il22/ recipients with GVHD. In all panels, data are combined or representative (TUNEL assay) of at least two independent
experiments and at least eight mice per group; bar graphs show mean and standard error. *p < .05, **p < .01, ***p < .001.
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IL-22 Protects ISCs and Regulates GVHDunaddressed topic of central importance is the effect of
the immune system on the precursor compartment of epithelial
stem and progenitor cells. Several cell types have been
proposed as the earliest stem cell population of intestinal epithe-
lium (Barker et al., 2007; Breault et al., 2008; Montgomery et al.,
2011; Sangiorgi and Capecchi, 2008; Sato et al., 2011; Simons
and Clevers, 2011; Zhu et al., 2009), with the Lgr5+ CBC cell
having demonstrated the capacity to regenerate entire crypt-
villus structures in vitro from just a single cell (Sato et al., 2011;
Sato et al., 2009; Simons and Clevers, 2011). In our study, GI
GVHD was found to specifically damage the ISC compartment,
and loss of ISCs was even more severe in the absence of host-
derived IL-22. These findings demonstrate that IL-22 can main-
tain intestinal epithelium during settings of inflammatory damage
at the level of the ISC. This IL-22-mediated protection of
ISCs during GVHD and our identification of IL-22R expression
on intestinal stem and progenitor cells further elucidate the
finding that ILCs can regulate intestinal epithelium (Sawa et al.,
2011) and extend the influence of ILCs and IL-22 to the ISC
compartment. We propose that Paneth cells in the stem cellniche may provide a constitutive basal signal for ISC mainte-
nance, whereas ILCs can provide an IL-22-dependent signal to
maintain the stem and progenitor cell pool and epithelial barrier
in the context of tissue damage and regeneration.
We found that recipient-derived IL-22 is critical for reducing
tissue damage during GVHD. In order for IL-22 and ILCs to exert
their protective functions within recipient epithelium post-BMT,
ILCs must be able to persist post-BMT despite lethal pretrans-
plant conditioning and hematopoietic reconstitution. Merad
et al. (2004) have described how recipient Langerhans cells
can persist in the skin of mice after T cell-depleted allogeneic
BMT despite donor hematopoietic reconstitution, and there is
increasing evidence for the importance of tissue-specific cells
in mediating local immune responses (Jiang et al., 2012). We
demonstrate here that intestinal ILCs are resistant to systemi-
cally lethal doses of TBI and that these ILCs can persist within
the lamina propria 3 months post-BMT, well after donor hemato-
poietic engraftment has occurred and even after the lamina
propria T cell compartment has reconstituted with donor-derived
cells. Interestingly, the T cell reconstitution in the peripheryImmunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc. 347
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IL-22 Protects ISCs and Regulates GVHDappeared to occur more rapidly than within the GI tract, given
that donor T cell chimerism was greater in the spleen than in
the small intestine lamina propria 2 months post-BMT. Although
donor-derived ILCs could be identified by 2 months post-BMT,
they represented the minority of the lamina propria ILC pool.
Moreover, even once the lamina propria T cell chimerism had
equilibrated to the T cell chimerism in the periphery by 3 months
post-BMT, the lamina propria ILCs remained largely of host
origin. Recipient-derived cells therefore comprise the majority
of the intestinal ILC compartment for at least 3 months after
BMT, further highlighting the significance of the loss of these
cells during GVHD.
In conclusion, IL-22 was produced post-BMT by IL-23-
responsive ILCs that were eliminated during GVHD, and defi-
ciency of IL-22 led to substantial loss of ISCs, increased
intestinal pathology, and loss of epithelial barrier function. These
findings reveal a reciprocal mucosal immunity network between
the epithelial compartment and the immune system, where
tissue damage leads to induction of IL-23, which can stimulate
the production of IL-22 by ILCs. This IL-22 production can then
protect the intestinal stem and progenitor cell compartment
and mature epithelium from inflammatory tissue damage.
However, during GVHD, there is loss of the IL-22-producing
ILCs necessary for limiting that inflammatory tissue damage.
The loss of tissue-protective ILCs represents a pathophysiologic
mechanism contributing to tissue damage in GVHD. These
findings could lead to targeted approaches for reduction of
clinical GVHD without limiting critical posttransplant functions
of the donor immune system such as graft versus leukemia or
lymphoma responses, antimicrobial immunity, facilitation of
engraftment, and promotion of immune reconstitution. Further
study of the IL-22-IL-22R axis may even facilitate the pretrans-
plant identification of patients who are at increased risk for the
development of GVHD. Finally, these findings may have broad
implications for pathogenesis and protection of ISCs during
other intestinal inflammatory diseases.EXPERIMENTAL PROCEDURES
Mice and Bone Marrow Transplantation
C57BL/6 (CD45.2 B6, H-2b), B6.SJL-Ptprca Pepcb/BoyJ (CD45.1 B6 con-
genic, H-2b), Il12b/ B6, BALB/c (H-2d), and LP (H-2b) mice were obtained
from the Jackson Laboratory. B6 and BALB/c Il22/ mice were provided by
Genentech, as was anti-IL-22 neutralizing antibody 8E11. Lgr5-LacZ and
Lgr5-GFP B6 mice were provided by H. Clevers (Barker et al., 2007). The
BMT procedure was performed as previously described (Petrovic et al.,
2004), with 850 cGy split-dosed lethal irradiation of BALB/c hosts receiving
bone marrow (5 3 106), T cell-depleted with anti-Thy-1.2 and low-TOX-M
rabbit complement (Cedarlane Laboratories), or performed with 1100 cGy
split-dosed lethal irradiation of B6 hosts receiving T cell-depleted bone
marrow (5 3 106) as well. Donor T cells (typically 1 3 106 B6 or 4 3 106 LP,
unless otherwise specified) were prepared for transplantation by harvesting
donor splenocytes and enriching for T cells by either nylon wool passage
(routinely >70% T cell purity) or by Miltenyi MACS purification of CD5
(routinely > 90%purity). Recipient miceweremonitored for survival and clinical
GVHD symptoms and were sacrificed for blinded histopathologic and flow
cytometric analysis as previously described (Petrovic et al., 2004). For
chimeric experiments, CD45.1 B6 congenic mice were lethally irradiated and
reconstituted with either wild-type or Il22/ CD45.2 marrow. Three months
later, donor reconstitution was confirmed by FACS of peripheral blood for
CD45.1 versus CD45.2, and chimeric mice were irradiated again (900 cGy,
split dose) and transplanted with LP marrow (10 3 106) and T cells (3 3 106).348 Immunity 37, 339–350, August 24, 2012 ª2012 Elsevier Inc.BMT protocols were approved by the MSKCC Institutional Animal Care and
Use Committee.
Histopathologic Analysis of GVHD Target Organs
GVHD mice were sacrificed, and the small intestine, large intestine, and
liver were removed, formalin-preserved, paraffin-embedded, sectioned, and
stained with hematoxylin and eosin (H&E). Scoring was performed as previ-
ously described (Petrovic et al., 2004).
Tissue Analyses and Flow Cytometry
Lymphoid organs from GVHD mice were processed into single-cell suspen-
sions, and lamina propria lymphocytes were isolated after dissociation of the
epithelium and digestion in DNaseI (Roche) and Collagenase D (Roche).
Surface staining was performed with the corresponding cocktail of antibodies,
and an eBioscience Fixation/Permeabilization kit was used per the manufac-
turer’s protocol for intracellular staining. FACS for IL-22R (rat-anti-mouse
IL-22Ra antibody 496514, R&D Systems) included both surface and intracel-
lular staining. Intracellular cytokine staining was performed with anti-IL-22
(1H8PWSR, eBioscience), anti-IFN-g (XMG1.2, BD PharMingen), or anti-
TNF-a (MP6-XT22, BD PharMingen) after 5 hr of restimulation with BD Golgi
Plug (1 ul/ml) and IL-23 (40 ng/ml) for IL-22 expression or phorbol-12-myris-
tate-13-acetate (50 ng/ml) and ionomycin (500 ng/ml) for IFN-g and TNF
expression. IL-22 and IL-23 ELISA were performed per the manufacturer’s
protocol (BioLegend) on either homogenates from small and large intestines
or on supernatants from intestines that were cultured at 37C overnight in
RPMI with FBS.
Immunohistochemistry, Immunofluorescence, TUNEL, LacZ,
and ISC Histology
Intestines were harvested from normal mice, formalin-fixed, and stained with
rat-anti-mouse IL-22Ra antibody 496514 (R&D Systems) versus isotype
control and/or polyclonal rabbit anti-human lysozyme 3.2.1.17 (Dakocytoma-
tion). Immunofluorescence secondary staining was performed with AF488 for
IL-22R and AF568 for lysozyme. TUNEL assay was performed on formalin-
fixed/paraffin-embedded tissue as described by Gavrieli et al. (1992). For
Lgr5-LacZ transplants, 2.5 cm segments of ileum were obtained, and staining
for presence of b-galactosidase (LacZ) was performed as per Barker et al.
(2007). In brief, small intestines were fixed in 1% formaldehyde, 0.2% glutaral-
dehyde, and 0.02% NP40 in PBS and then incubated with b-galactosidase
substrate. Tissues were then fixed again in 4% PFA in PBS and paraffin-
embedded, and sections were counterstained with Nuclear Fast Red (Vector).
For assessing ISCs in nonreporter mice, crypt base columnar intestinal stem
cells were identified as reported by their morphology and their location at
the crypt base between Paneth cells (Barker et al., 2007).
Quantitative PCR
Reverse transcription-PCR was done with a QuantiTect reverse transcription
kit (QIAGEN). For real-time PCR, specific primer and probe sets were obtained
from Applied Biosystems as follows: Beta-actin: Mm01205647_g1, Reg3b:
Mm00440616_g1, and Reg3g: Mm00441127_m1. PCR was done on ABI
7500 (Applied Biosystems) with TaqMan Universal PCR Master Mix (Applied
Biosystems). Relative amounts of Reg3g and Reg3b mRNA were calculated
by the comparative DC(t) method.
FITC-Dextran Assay
Mice were kept without food and water for 4 hr and then FITC-dextran (#FD4-
1G, Sigma) was administered by oral gavage at a concentration of 40 mg/ml in
phosphate-buffered saline (PBS) in 400 ul (16mg) per mouse (800mg/kg).
Four hours later, plasma was collected from peripheral blood, then mixed
1:1 with PBS and analyzed on a plate reader at an excitation wavelength of
485 nm and an emission wavelength of 535 nm.
Statistics
Bars and error bars represent the means + SEM, respectively, for the various
groups. Survival data were analyzed with the Mantel-Cox log-rank test. For
nonsurvival pointwise analyses, unpaired t test was used for comparisons
between two experimental groups, or nonparametric Mann-Whitney U test
was used for non-Gaussian distributions, and ANOVA was used for
Immunity
IL-22 Protects ISCs and Regulates GVHDcomparisons with more than two groups. Survival transplants were performed
with 10–38 mice per group, and all other experiments were performed at least
twice with at least six mice per group.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
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